# A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract

> **NCT04539548** · PHASE3 · COMPLETED · sponsor: **Ocular Therapeutix, Inc.** · enrollment: 65 (actual)

## Conditions studied

- Cataract

## Interventions

- **DRUG:** Dextenza Ophthalmic Insert
- **DRUG:** Prednisolone acetate ophthalmic suspension USP 1%

## Key facts

- **NCT ID:** NCT04539548
- **Lead sponsor:** Ocular Therapeutix, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-04
- **Primary completion:** 2023-12-21
- **Final completion:** 2023-12-21
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2024-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04539548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04539548, "A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04539548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*